
Researchers identify a blood biomarker linked to worse outcomes in diffuse cutaneous systemic sclerosis, paving the way for early detection and treatment.
Kristel Tjandra is a writer for the Yale School of Medicine Editorial Department.

Published: April 9th 2025 | Updated: